Nymox Pharmaceutical Corporation
NYMXF
$0.1364
$0.026424.00%
OTC PK
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 701.70% | -30.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 378.30% | -7.82% | |||
| Operating Income | -378.30% | 7.82% | |||
| Income Before Tax | -412.64% | 6.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -412.64% | 6.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -412.64% | 6.67% | |||
| EBIT | -378.30% | 7.82% | |||
| EBITDA | -379.43% | 7.92% | |||
| EPS Basic | -416.96% | 8.20% | |||
| Normalized Basic EPS | -374.29% | 7.89% | |||
| EPS Diluted | -416.96% | 8.20% | |||
| Normalized Diluted EPS | -374.29% | 7.89% | |||
| Average Basic Shares Outstanding | -0.40% | 0.98% | |||
| Average Diluted Shares Outstanding | -0.40% | 0.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||